Audra J.
Soloway

Co-chair of the Securities Litigation and Enforcement Group, Audra Soloway focuses her practice on securities litigation, corporate internal investigations and enforcement proceedings and regulatory defense. Audra has extensive experience representing companies and their officers and directors in shareholder class actions, derivative litigations and individual actions, as well as arbitrations. Audra also represents clients in investigations and enforcement proceedings brought by the Securities Exchange Commission and state securities regulators.

Audra speaks and writes extensively about the federal securities laws. She has authored dozens of articles, and is a co-author of the treatise Federal Securities Litigation: A Deskbook for the Practitioner, 3rd edition. She also serves as Co-Chair of the New York City Bar Securities Litigation Committee.

Audra is a five-time Law360 MVP, in the Securities and Class Action categories (2017, 2022, 2023, 2024, 2025), and has been named “Securities Litigator of the Year” by Euromoney’s Women in Business Law Awards (2022) and a “Class Action/Mass Tort Litigation Trailblazer” by The National Law Journal (2023). Audra is ranked in Chambers USA for New York Securities Litigation, where clients report that she is “an excellent lawyer and strategist” who is “brilliant to work with” and "an encyclopedia of the securities laws and a dogged advocate with very good judgment.” She is also ranked by Legal 500 US for Securities Litigation – Defense and Financial Services Litigation and as a “Litigation Star” in Benchmark Litigation. Audra was featured in Crain’s New York Business’ inaugural list of Leading Women Lawyers in New York City (2017), which celebrates talented female attorneys in the New York City metropolitan area. She was listed in Lawdragon’s “500 Leading Lawyers in America” list (2022-2025) and in its “500 Leading Litigators in America” list (2024-2025).

Audra’s significant representations of corporations and boards of directors in securities litigation, include:

• AEA Investors LP in the favorable resolution of a securities class action brought in the Southern District of New York by shareholders of AEA portfolio company Evoqua Water Technologies arising out of Evoqua’s initial and secondary public offerings.
• AIG in the resolution of a shareholder lawsuit in the Southern District of New York concerning allegations of accounting fraud and bid rigging;
• Alexion Pharmaceuticals, the country’s then-largest orphan drug company, and its executives in the resolution of a securities class action and voluntary dismissal of a derivative action in the District of Connecticut alleging misrepresentations and omissions about Alexion’s blood disorder drug Soliris.
• Amazon.com, Inc. in the dismissal, with prejudice, of a securities class action in the Western District of Washington alleging that the defendants made false and misleading statements or omissions regarding Amazon’s private-label business practices, regarding its alleged improper use of third-party sellers’ data.
• AR Global Investments, LLC and certain current and former executives in the dismissal of shareholder lawsuits, affirmed on appeal, filed in New York Supreme Court and the Southern District of New York challenging statements in the proxy issued in the merger of two AR Global-sponsored REITs, American Finance Trust (AFIN) and Retail Centers of America.
• Avis Budget Group, Inc.:
  • and certain directors and officers in shareholder derivative litigation concerning a stock repurchase program; and
  • in a securities class action in the District of New jersey alleging that the company made materially false and misleading statements, and failed to disclose material information, regarding its fleet management strategy.
• Bank of America in the successful resolution of litigations by shareholders in the Southern District of New York, the SEC, and the New York Attorney General arising out of its $50 billion merger with Merrill Lynch.
• Bank of New York Mellon in the dismissal of a high-stakes investor class action in the Southern District of New York alleging that the bank aided and abetted a pyramid scheme involving purported cryptocurrency OneCoin.
• Biogen Inc. and certain current and former executives in a securities class action in the District of Massachusetts alleging that the defendants made false and misleading statements about its Alzheimer’s drug aducanumab during the FDA approval process.
• Carnival Corp. in the dismissal of a shareholder suit in New York Supreme Court alleging that Carnival’s board failed to prevent U.S. environmental law violations committed by Princess Cruise Lines.
• Carrier Global Corporation in securing the dismissal with prejudice of a putative class action in the District of Connecticut brought against Raytheon Technologies Corporation (formerly United Technologies Corporation (UTC)), Otis Worldwide Corporation, and Carrier for the alleged improper conversion of employee equity awards in certain UTC compensation plans in connection with UTC’s spin-off of Carrier and Otis as separate public companies.
• The Citco Group of Companies in litigation filed by investors in hedge funds that collapsed during the credit crisis.
• Citigroup in multiple matters, including:
  • the favorable resolution of a 15-year litigation across seven different cases in New York and French courts concerning a FINRA dispute with a former Citigroup Global Markets client;
  • regulatory investigations and civil litigations relating to the sales and marketing of the ASTA/MAT and Falcon hedge funds;
  • class action litigation filed by investors in the CSO hedge fund, concerning its disclosures to investors following a significant debt transaction;
  • a series of FINRA arbitrations and federal and state court actions by issuers of auction rate securities alleging that Citigroup had failed to disclose the risks of these products in advance of the market collapse in 2008; and
  • defense of securities fraud class actions against Citigroup and Jack Grubman relating to research coverage of the telecommunications industry, including WorldCom.
• ExxonMobil Corporation and certain of its former executives in a federal securities class action in the Northern District of Texas alleging that the company made a series of false and misleading statements that artificially inflated the company’s stock price, costing stockholders billions of dollars.
• Fireman Capital Partners in a class action by former Left Coast Ventures (LCV) shareholders in the Delaware Court of Chancery, alleging that Fireman Capital breached its fiduciary duty by amending convertible notes and warrants before LCV’s SPAC merger, diverting part of the merger consideration from LCV shareholders to itself.
• GOL Linhas Aereas Inteligentes S.A., a Brazilian airline, in the dismissal of a consolidated putative securities class action in the Eastern District of New York alleging that GOL misstated the adequacy of its internal controls and ability to continue as a going concern.
• Goldman Sachs in:
  • its victory at the U.S. Supreme Court in a securities class action involving the standard for disproving price impact in connection with class certification in a securities class action; and
  • a securities class action and shareholder derivative litigation in the Southern District of New York relating to large bond offerings in Southeast Asia.
• HCP, Inc., a REIT invested primarily in real estate serving the healthcare industry, in the dismissal of a putative securities class action and related derivative litigation in the Northern District of Ohio alleging that HCP and its current and former directors failed to make sufficient disclosures about the company’s financial condition and portfolio.
• the outside directors of JPMorgan Chase in:
  • the dismissal of a derivative claim in the Delaware Court of Chancery alleging the defendants breached their fiduciary duties by ignoring alleged “red flags” regarding purported violations on the Zelle payments platform of the Electronic Fund Transfer Act (EFTA) and related regulations;
  • the dismissal with prejudice of a derivative action in the Southern District of New York brought by a pension fund alleging that the defendants breached fiduciary duties of oversight in connection with former JPMorgan client Jeffrey Epstein’s criminal activity; and
  • the dismissal of a shareholder derivative lawsuit in New York Supreme Court stemming from the bank’s 2020 resolutions with various regulators over various financial “spoofing” trading violations.
• Kirkland Lake Gold and its former CEO, in defeating class certification and winning summary judgment in a securities fraud class action in the Southern District of New York arising from alleged misrepresentations about its strategy for future acquisitions of gold mining companies.
• Lockheed Martin Corporation and certain of its senior executives in a securities fraud class action in the Southern District of New York concerning cost overruns in certain government contracts.
• NextEra Energy Inc., the world’s largest public utility company, and certain current and former executives in the dismissal with prejudice of a securities class action in the Southern District of Florida alleging misstatements about the political activities of Florida Power and Light (FPL) and its former outside political consulting firm, and in related derivative litigation.
• Novo Nordisk and certain executives in:
  • a putative securities class action in the District of New Jersey alleging that the defendants made false or misleading statements about the company’s GLP-1 growth prospects and the impact of compounded semaglutide; and
  • a putative securities class action in the District of New Jersey alleging that the defendants misled investors about a clinical trial for CagriSema, a novel combination therapy for obesity.
• PayPal Holdings, Inc. and several of its directors and executives in the dismissal of a securities class action and related shareholder derivative actions in the Northern District of California alleging that the defendants made misrepresentations and omissions about the PayPal’s regulatory compliance.
• Portola Pharmaceuticals Inc. and certain of its officers and directors in the resolution of a securities class action in the Northern District of California alleging that the company made misrepresentations by improperly recognized revenue for its lead drug, Andexxa.
• Regeneron Pharmaceuticals and certain of its executives in a securities fraud class action in the Southern District of New York alleging that the defendants made false and misleading statements and failed to disclose material facts relating to its eye disease drugs EYLEA® and EYLEA HD®.
• Restaurant Brands International (RBI), 3G Capital and certain of their executives and board members in the dismissal of a securities class action in New York Supreme Court alleging that the company misrepresented and/or failed to disclose that several Tim Hortons initiatives were not having a positive impact on sales in the quarter of the offerings. The New York Supreme Court Appellate Division unanimously reversed the trial court order denying the motion to dismiss, and directed the trial court to enter judgment dismissing the case.
• Riskified, Ltd. and its officers and directors in the dismissal of a securities class action in the Southern District of New York based on purported omissions and misleading statements issued in connection with Riskified’s 2021 IPO.
• Santa Barbara Hospitality, a Curacao hotel owner, in obtaining a victory at arbitration in a dispute with Hyatt concerning the hotel’s management.
• Sealed Air Corporation, a Fortune 500 packaging company, in a securities class action in the District of New Jersy alleging misstatements about potential liabilities related to its acquisition of the W.R. Grace packaging business.
• Snap, Inc.:
  • and several of its directors and executives in the favorable resolution, following three motions to dismiss, of a securities class action in the Central District of California concerning Snap’s preparation for Apple’s rollout of new privacy changes; and
  • and several of its officers in a putative federal securities class action in the Central District of California alleging that the defendants made false and misleading statements about advertising revenue.
• Steven A. Cohen and SAC Capital (now Point72 Asset Management) in civil and regulatory matters alleging insider trading, including class action litigation filed by a class of contemporaneous traders alleging insider trading in the securities of Elan and Wyeth.
• Teladoc Health, Inc. and certain current and former executives and directors in:
  • a securities fraud class action and related shareholder derivative litigation in the Southern District of New York alleging that the company made false and misleading statements concerning advertising spend and membership metrics for BetterHelp;
  • the dismissal of a securities lawsuit in the Southern District of New York concerning Teladoc’s integration with Livongo Health following its merger;
  • the dismissal of a securities class action in New York Supreme Court alleging that the registration statement and prospectus issued in connection with Teladoc’s merger with Livongo Health contained material misstatements and omissions about Teladoc’s potential membership growth after the merger; and
  • the dismissal of a securities class action and related shareholder derivative action in the Southern District of New York arising out of alleged misconduct by the company’s former CFO.
• Telus International (Cda) Inc. and certain of its senior executives in a putative securities class action in the Southern District of New York alleging that the defendants made false and misleading statements regarding the company’s AI capabilities.
• Vanda Pharmaceuticals, Inc. and certain of its current and former officers in the resolution of a securities class action and a consolidated derivative action in the Eastern District of New York alleging that the defendants made statements that were false and/or misleading with respect to both the company’s marketing practices and the state of clinical trials.
• Vertiv Holdings Co. and its directors and officers in a securities class action and related shareholder derivative litigation in the alleging that the defendants made false and misleading projections which were revealed to be false when it failed to meet its guidance due to supply chain issues and inflation.
• Virtu Financial, Inc.:
  • in a securities fraud lawsuit in the Southern District of New York alleging that Virtu and other broker-dealers engaged in market manipulation by spoofing shares of a pharmaceutical company whose shares trade on over-the-counter markets; and
  • and certain of its executives and officers in a securities class action in the Eastern District of New York alleging that the defendants made false statements regarding Virtu’s commitment to safeguarding client trading information, which resulted in an SEC investigation and enforcement action.
• XPLR Infrastructure, LP in a securities class action in the Southern District of California alleging that the company and its executives made materially false and misleading statements about its financial health and business model.
• Zuora Inc., a cloud-based subscription management platform, in the successful global resolution of securities class actions in the Northern District of California alleging that the company made misrepresentations concerning its integration of its two flagship products, Zuora Billing and Zuora RevPro.

Her representations of various senior executives defending fraud claims, include:

• Carlos Ghosn, the former chairman of Nissan Motor Company, in a class action filed by shareholders alleging that executives misstated the value of their compensation.
• Nicholas Schorsch, the founder and former CEO of American Realty Capital Properties (ARCP), in class action and individual securities fraud cases and derivative litigations concerning ARCP’s accounting restatement.
• Chip Wilson, the founder and former CEO of Canadian athletic-wear manufacturer lululemon athletica, in securities fraud class action and derivative litigation concerning disclosures of product recalls.

Her representations of numerous syndicates of underwriters in Securities Act class actions arising from public offerings of debt and equity, include:

• 37 underwriters, led by Citigroup, Goldman Sachs, Morgan Stanley and Barclays, in the successful dismissal by a Michigan state court of Securities Act claims arising from the initial public offering of Ally Financial.
• the underwriters, led by Citigroup, Carnegie AS and China Internal Capital Corporation, in securing the dismissal of a class action in the Southern District of New York arising from the initial public offering of Norwegian software company Opera Limited.
• 14 underwriters, led by Citigroup, Goldman Sachs, JPMorgan and Bank of America/Merrill Lynch, in the dismissal of Securities Act claims in Texas state court arising from the initial and secondary offerings of Venator Materials PLC.
• 16 underwriters, led by Citigroup, Credit Suisse, and Goldman Sachs, in the resolution of Securities Act claims in Colorado state court arising from the initial public offering of the oil drilling company Jagged Peak.
• five underwriters, led by Bank of Montreal, Royal Bank of Canada, and Goldman Sachs, in the successful defense of Securities Act claims in District of Colorado arising from the initial public offering of the mining company Gatos Silver, Inc.
• the underwriters, led by Citigroup, in the dismissal of securities fraud claims in the Southern District of New York arising from the initial public offering of China-based company Canaan Inc.
• the underwriters in a securities class action in the Southern District of New York related to a $609 million secondary offering of shares of infrastructure and energy company Abengoa S.A.

Audra is active in pro bono work and the community. She co-chairs the firm’s Public Matters Committee. She devotes hundreds of hours each year to pro bono work, and has secured important victories in particular for organizations and families involved in the New York City child welfare system. Most recently, she represented amici medical experts in the New Jersey Supreme Court’s State v. Nieves, which affirmed the exclusion of Shaken Baby Syndrome/Abusive Head Trauma (SBS/AHT) expert testimony as insufficiently reliable to be presented to a jury. Audra also serves on the boards of the Family Justice Law Center and the Stephen Wise Free Synagogue.